B of A Securities Rates Immix Biopharma (IMMX) buy

The firm sets a $27 price target as shares trade around $9.13, a 172.45% upside from the current price.

By EarningsIQ Research Desk · Published Jun 18, 2026, 7:01 AM EDT · Updated Jun 24, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

B of A Securities rated Immix Biopharma, Inc. ($IMMX) "buy" with a $27 price target on June 18, 2026.

Since the rating, $IMMX is up 11.5% after 1 week, up 0.9% after 1 month and down 8.5% to date (from the $8.72 close on Jun 18, 2026).

IMMX Immix Biopharma, Inc.

$7.98 +46.96% year to date

Daily close · Oct 16, 2026

Key Points

On June 18, 2026, B of A Securities reiterated its buy rating on Immix Biopharma with a $27 price target.
B of A Securities's $27 price target implies 172.45% upside from Immix Biopharma, Inc.'s ($IMMX) current $9.91 share price.
Immix Biopharma, trading on NasdaqCM under IMMX, has a market cap of about $649.96 million and a 52-week high of $11.61.
Insider buying activity on May 22, 2026, included multiple purchases, while analysts like LifeSci Capital also initiated buy ratings.

Get $IMMX trade alerts by text

We text you when insiders, Congress or big funds trade $IMMX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Immix Biopharma, Inc. alert may contain errors. Disclosures

B of A Securities reiterated its buy rating on Immix Biopharma, Inc. (NasdaqCM: IMMX) on June 18, 2026, setting a price target of $27. This comes as shares of the biotechnology firm trade near $9.13.

Other Institutional Activity in Immix Biopharma

Janus Henderson Group PLC grew its holdings by 880,434 shares, bringing its total to 4,802,002 shares valued at about $43.7 million. Saturn V Capital Management LP added 694,416 shares, ending with 3,693,585 shares worth approximately $33.6 million. Eventide Asset Management, LLC maintained its position with 2,549,019 shares valued at $23.2 million. Vanguard Capital Management LLC acquired 1,787,994 shares, a new position valued at $16.3 million. Conversely, Marshall Wace, LLP reduced its stake by 337,191 shares, holding 1,641,552 shares valued around $14.9 million.

Immix Biopharma, Inc. Stock Down 20.7%

Shares of Immix Biopharma are trading on NasdaqCM under the ticker IMMX, with a recent spot price of $9.13. The company has a market cap of approximately $649.96 million and a beta of 0.105, indicating low volatility. Immix Biopharma's stock has ranged from a 52-week low of $1.94 to a high of $11.61. The 50-day moving average is $9.23, and the 200-day moving average is $6.26. The firm's current ratio is 8.76, and it has a debt-to-equity ratio of 1.23.

12-month forecast

$IMMX price target

Immix Biopharma, Inc. daily closes and this analyst's $27 target. Not advice.

Insider Buying and Selling at Immix Biopharma, Inc.

On May 22, 2026, several insiders bought shares of Immix Biopharma. Helen Adams acquired a total of 18,750 shares, while Jane Buchan purchased 12,500 shares. Magda Marquet and Jason Hsu each bought 6,250 shares. Yekaterina Chudnovsky also purchased 12,500 shares. These transactions were not part of a pre-arranged trading plan.

Analysts Set New Price Targets

On June 18, 2026, B of A Securities reiterated its buy rating with a $27 price target. The day before, LifeSci Capital initiated coverage with a buy rating and a $19 target. On May 22, 2026, HC Wainwright & Co. maintained its buy rating with a $20 target. The consensus among five analysts is a buy rating, with a mean price target of $18.46.

About Immix Biopharma

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, California. It focuses on developing therapies for light chain amyloidosis and immune-mediated diseases, primarily in the United States and Australia. The company's leading product candidate is NXC-201, aimed at treating relapsed/refractory AL amyloidosis. Founded in 2012, the company is led by CEO Dr. Ilya Rachman.

Bottom Line

Immix Biopharma is attracting attention with its promising drug pipeline and recent analyst support. B of A Securities' reiterated buy rating with a $27 price target suggests confidence in the company's future prospects. Investors should note that 13F filings and analyst ratings are backward-looking indicators and may not reflect the current market conditions.